{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:47:01Z","timestamp":1793933221094,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The evidence supporting rifampin combination therapy in prosthetic joint infections (PJI) is limited due to the lack of controlled studies. The aim of this study is to evaluate the effect of adding rifampin to conventional antimicrobial therapy in early staphylococcal PJIs treated with debridement and retention of the implant (DAIR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter randomized controlled trial, 99 patients with PJI after hip and knee arthroplasties were enrolled. They were randomly assigned to receive rifampin or not in addition to standard antimicrobial treatment with cloxacillin or vancomycin in case of methicillin resistance. The primary endpoint was no signs of infection after 2\u2009years of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-eight patients were included in the final analyses. There were no differences in patient characteristics or comorbidities between the two groups. There was no significant difference in remission rate between the rifampin combination group (17 of 23 (74%)) and the monotherapy group (18 of 25 (72%), relative risk 1.03, 95% confidence interval 0.73 to 1.45,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.88).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This trial has not proven a statistically significant advantage by adding rifampin to standard antibiotic treatment in acute staphylococcal PJIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The Regional Ethics Committee and the Norwegian Medicines Agency approved the study (EudraCT 2005-005494-29), and the study was registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      at Jan 18, 2007 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00423982?term=rifampin+combination+therapy+versus&amp;draw=2&amp;rank=1\">NCT00423982<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13018-020-01877-2","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T09:03:27Z","timestamp":1598605407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-5371","authenticated-orcid":false,"given":"\u00d8ystein Espeland","family":"Karlsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Borgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Bragnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wender","family":"Figved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Gr\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Rydinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnur","family":"Snorrason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Wangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Wits\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Westberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"issue":"Suppl 3","key":"1877_CR1","first-page":"144","volume":"89","author":"SM Kurtz","year":"2007","unstructured":"Kurtz SM, et al. Future clinical and economic impact of revision total hip and knee arthroplasty. J Bone Joint Surg Am. 2007;89(Suppl 3):144\u201351.","journal-title":"J Bone Joint Surg Am"},{"issue":"12","key":"1877_CR2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199009203231206","volume":"323","author":"WH Harris","year":"1990","unstructured":"Harris WH, Sledge CB. Total hip and total knee replacement (2). N Engl J Med. 1990;323(12):801\u20137.","journal-title":"N Engl J Med"},{"issue":"14","key":"1877_CR3","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMra035415","volume":"350","author":"RO Darouiche","year":"2004","unstructured":"Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350(14):1422\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"1877_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/dki016","volume":"55","author":"M Bassetti","year":"2005","unstructured":"Bassetti M, et al. Linezolid in the treatment of gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55(3):387\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"1877_CR5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/374554","volume":"36","author":"JR Lentino","year":"2003","unstructured":"Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis. 2003;36(9):1157\u201361.","journal-title":"Clin Infect Dis"},{"issue":"24","key":"1877_CR6","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2106\/JBJS.L.00789","volume":"95","author":"B Zmistowski","year":"2013","unstructured":"Zmistowski B, et al. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am. 2013;95(24):2177\u201384.","journal-title":"J Bone Joint Surg Am"},{"issue":"8 Suppl","key":"1877_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.arth.2012.02.022","volume":"27","author":"SM Kurtz","year":"2012","unstructured":"Kurtz SM, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplast. 2012;27(8 Suppl):61\u20135 e1.","journal-title":"J Arthroplast"},{"issue":"5","key":"1877_CR8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/17453674.2012.733918","volume":"83","author":"H Dale","year":"2012","unstructured":"Dale H, et al. Increasing risk of prosthetic joint infection after total hip arthroplasty. Acta Orthop. 2012;83(5):449\u201358.","journal-title":"Acta Orthop"},{"issue":"7","key":"1877_CR9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.arth.2007.10.017","volume":"23","author":"SM Kurtz","year":"2008","unstructured":"Kurtz SM, et al. Infection burden for hip and knee arthroplasty in the United States. J Arthroplast. 2008;23(7):984\u201391.","journal-title":"J Arthroplast"},{"issue":"2","key":"1877_CR10","first-page":"185","volume":"6","author":"A Trampuz","year":"2005","unstructured":"Trampuz A, Zimmerli W. New strategies for the treatment of infections associated with prosthetic joints. Curr Opin Investig Drugs. 2005;6(2):185\u201390.","journal-title":"Curr Opin Investig Drugs"},{"issue":"3","key":"1877_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/318502","volume":"32","author":"DN Fisman","year":"2001","unstructured":"Fisman DN, et al. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis. 2001;32(3):419\u201330.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1877_CR12","first-page":"1","volume":"55","author":"E Moran","year":"2007","unstructured":"Moran E, et al. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Inf Secur. 2007;55(1):1\u20137.","journal-title":"J Inf Secur"},{"issue":"4","key":"1877_CR13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2106\/00004623-199604000-00005","volume":"78","author":"DT Tsukayama","year":"1996","unstructured":"Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am. 1996;78(4):512\u201323.","journal-title":"J Bone Joint Surg Am"},{"issue":"11-12","key":"1877_CR14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3109\/00365540903186207","volume":"41","author":"A Stefansdottir","year":"2009","unstructured":"Stefansdottir A, et al. Microbiology of the infected knee arthroplasty: report from the Swedish knee arthroplasty register on 426 surgically revised cases. Scand J Infect Dis. 2009;41(11-12):831\u201340.","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"1877_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0142-9612(87)90077-9","volume":"8","author":"AG Gristina","year":"1987","unstructured":"Gristina AG, et al. Adhesive colonization of biomaterials and antibiotic resistance. Biomaterials. 1987;8(6):423\u20136.","journal-title":"Biomaterials"},{"issue":"16","key":"1877_CR16","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645\u201354.","journal-title":"N Engl J Med"},{"issue":"9276","key":"1877_CR17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(01)05321-1","volume":"358","author":"PS Stewart","year":"2001","unstructured":"Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135\u20138.","journal-title":"Lancet"},{"key":"1877_CR18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fcimb.2014.00178","volume":"4","author":"JL Lister","year":"2014","unstructured":"Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Front Cell Infect Microbiol. 2014;4:178.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"1877_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/17453674.2012.678801","volume":"83","author":"M Westberg","year":"2012","unstructured":"Westberg M, Grogaard B, Snorrason F. Early prosthetic joint infections treated with debridement and implant retention: 38 primary hip arthroplasties prospectively recorded and followed for median 4\u2009years. Acta Orthop. 2012;83(3):227\u201332.","journal-title":"Acta Orthop"},{"issue":"8","key":"1877_CR20","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s11999-010-1291-y","volume":"468","author":"JP Van Kleunen","year":"2010","unstructured":"Van Kleunen JP, et al. Irrigation and debridement and prosthesis retention for treating acute periprosthetic infections. Clin Orthop Relat Res. 2010;468(8):2024\u20138.","journal-title":"Clin Orthop Relat Res"},{"key":"1877_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.micpath.2015.11.031","volume":"93","author":"BS Fazly Bazzaz","year":"2016","unstructured":"Fazly Bazzaz BS, et al. Antibacterial efficacy of rifampin loaded solid lipid nanoparticles against Staphylococcus epidermidis biofilm. Microb Pathog. 2016;93:137\u201344.","journal-title":"Microb Pathog"},{"issue":"7","key":"1877_CR22","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1128\/AAC.00300-08","volume":"52","author":"DJ Riedel","year":"2008","unstructured":"Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(7):2463\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"1877_CR23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","volume":"279","author":"W Zimmerli","year":"1998","unstructured":"Zimmerli W, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-body infection (FBI) study group. JAMA. 1998;279(19):1537\u201341.","journal-title":"JAMA"},{"issue":"8","key":"1877_CR24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10096-010-0952-9","volume":"29","author":"OC El Helou","year":"2010","unstructured":"El Helou OC, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis. 2010;29(8):961\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"1877_CR25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","volume":"53","author":"E Senneville","year":"2011","unstructured":"Senneville E, et al. Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011;53(4):334\u201340.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1877_CR26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1469-0691.2005.01230.x","volume":"11","author":"JE Berdal","year":"2005","unstructured":"Berdal JE, et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect. 2005;11(10):843\u20135.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"1877_CR27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cid\/cis746","volume":"56","author":"J Lora-Tamayo","year":"2013","unstructured":"Lora-Tamayo J, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56(2):182\u201394.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1877_CR28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/17453674.2015.1026756","volume":"86","author":"A Holmberg","year":"2015","unstructured":"Holmberg A, et al. 75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections. Acta Orthop. 2015;86(4):457\u201362.","journal-title":"Acta Orthop"},{"issue":"11","key":"1877_CR29","doi-asserted-by":"crossref","first-page":"993 e7","DOI":"10.1016\/j.amjmed.2006.03.036","volume":"119","author":"J Barberan","year":"2006","unstructured":"Barberan J, et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med. 2006;119(11):993 e7\u201310.","journal-title":"Am J Med"},{"issue":"5","key":"1877_CR30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkv481","volume":"71","author":"E Tornero","year":"2016","unstructured":"Tornero E, et al. Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention. J Antimicrob Chemother. 2016;71(5):1395\u2013401.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1877_CR31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/cid\/ciw665","volume":"63","author":"R Pushkin","year":"2016","unstructured":"Pushkin R, et al. A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: a newly identified drug-drug interaction. Clin Infect Dis. 2016;63(12):1599\u2013604.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1877_CR32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/CMR.00034-09","volume":"23","author":"GN Forrest","year":"2010","unstructured":"Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010;23(1):14\u201334.","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"1877_CR33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archinte.168.8.805","volume":"168","author":"J Perlroth","year":"2008","unstructured":"Perlroth J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med. 2008;168(8):805\u201319.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1877_CR34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1302\/0301-620X.99B5.BJJ-2016-0851.R1","volume":"99-B","author":"D Akgun","year":"2017","unstructured":"Akgun D, et al. High failure rates in treatment of streptococcal periprosthetic joint infection: results from a seven-year retrospective cohort study. Bone Joint J. 2017;99-B(5):653\u20139.","journal-title":"Bone Joint J"},{"issue":"10","key":"1877_CR35","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1128\/AAC.48.10.4016-4019.2004","volume":"48","author":"SA Shelburne","year":"2004","unstructured":"Shelburne SA, et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother. 2004;48(10):4016\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10121","key":"1877_CR36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","volume":"391","author":"GE Thwaites","year":"2018","unstructured":"Thwaites GE, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10121):668\u201378.","journal-title":"Lancet"},{"issue":"5","key":"1877_CR37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1302\/0301-620X.99B5.BJJ-2016-0562.R2","volume":"99-B","author":"G Grammatopoulos","year":"2017","unstructured":"Grammatopoulos G, et al. Functional outcome of debridement, antibiotics and implant retention in periprosthetic joint infection involving the hip: a case-control study. Bone Joint J. 2017;99-B(5):614\u201322.","journal-title":"Bone Joint J"},{"issue":"2","key":"1877_CR38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jac\/dkh033","volume":"53","author":"L Bernard","year":"2004","unstructured":"Bernard L, et al. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother. 2004;53(2):127\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"1877_CR39","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2106\/00004623-199809000-00009","volume":"80","author":"JR Crockarell","year":"1998","unstructured":"Crockarell JR, et al. Treatment of infection with debridement and retention of the components following hip arthroplasty. J Bone Joint Surg Am. 1998;80(9):1306\u201313.","journal-title":"J Bone Joint Surg Am"},{"issue":"11","key":"1877_CR40","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1302\/0301-620X.99B11.BJJ-2017-0088.R1","volume":"99-B","author":"SJ Tsang","year":"2017","unstructured":"Tsang SJ, et al. Outcomes following debridement, antibiotics and implant retention in the management of periprosthetic infections of the hip: a review of cohort studies. Bone Joint J. 2017;99-B(11):1458\u201366.","journal-title":"Bone Joint J"},{"issue":"4","key":"1877_CR41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/17453674.2013.823589","volume":"84","author":"JW Kuiper","year":"2013","unstructured":"Kuiper JW, et al. Prosthetic joint-associated infections treated with DAIR (debridement, antibiotics, irrigation, and retention): analysis of risk factors and local antibiotic carriers in 91 patients. Acta Orthop. 2013;84(4):380\u20136.","journal-title":"Acta Orthop"},{"issue":"4","key":"1877_CR42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0883-5403(97)90199-6","volume":"12","author":"MA Mont","year":"1997","unstructured":"Mont MA, et al. Multiple irrigation, debridement, and retention of components in infected total knee arthroplasty. J Arthroplast. 1997;12(4):426\u201333.","journal-title":"J Arthroplast"},{"issue":"4","key":"1877_CR43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/17453674.2014.927729","volume":"85","author":"DJ Moojen","year":"2014","unstructured":"Moojen DJ, et al. Similar success rates for single and multiple debridement surgery for acute hip arthroplasty infection. Acta Orthop. 2014;85(4):383\u20138.","journal-title":"Acta Orthop"},{"issue":"8","key":"1877_CR44","doi-asserted-by":"crossref","first-page":"e70499","DOI":"10.1371\/journal.pone.0070499","volume":"8","author":"JF Moxnes","year":"2013","unstructured":"Moxnes JF, et al. Methicillin-resistant Staphylococcus aureus (MRSA) is increasing in Norway: a time series analysis of reported MRSA and methicillin-sensitive S. aureus cases, 1997-2010. PLoS One. 2013;8(8):e70499.","journal-title":"PLoS One"},{"issue":"3","key":"1877_CR45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-121-3-199408010-00008","volume":"121","author":"SN Goodman","year":"1994","unstructured":"Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994;121(3):200\u20136.","journal-title":"Ann Intern Med"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-020-01877-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-020-01877-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-020-01877-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T20:03:33Z","timestamp":1630094613000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-020-01877-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1186\/s13018-020-01877-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23809\/v1","asserted-by":"object"}]},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regional Ethics Committee and the Norwegian Medicines Agency have approved this study. All patients participating approved by written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}